Lifetime Citizen Portal Access — AI Briefings, Alerts & Unlimited Follows
Meeting at HHS building highlights push to reduce regulatory barriers for health tech firms
Loading...
Summary
At a meeting at the U.S. Department of Health and Human Services building, Robert F. Kennedy Jr. described discussions with about a dozen health technology CEOs about apps and wearables and said HHS should ease regulatory barriers so the companies can operate and “flourish in the marketplace.”
Robert F. Kennedy Jr., who identified himself in the transcript as “your HHS secretary,” said at a meeting at the U.S. Department of Health and Human Services building that he met with about a dozen chief executives of health technology companies to discuss digital tools and wearables aimed at giving Americans more control over their health care.
Kennedy summarized the discussion in the transcript: "Hey. I'm Robert f Kennedy junior, your HHS secretary. And today, I had 1 of the most exciting meetings that I've had since taking office in this building. It was a meeting with about a dozen CEOs of health tech companies who are entrepreneurs who have a vision of transforming and disrupting American health care and turning our country from a sick care system into a health care system. We heard from companies that operate health care apps that summarize your medical records on your telephone and give you real time health data on what you eat, how you feel, how you're sleeping."
He described companies that make monitoring devices and the kinds of data they can provide: "We heard from companies that create wearables that can tell you your blood pressure, whether you have atrial fibrillations. All these things provide the kind of transparency and the capacity for Americans to take control of their own health care. We're determined here at HHS to sweep away the regulatory barriers and allow these companies to function and flourish in the marketplace."
The transcript records the topics discussed — medical-record–summary apps, consumer wearables with cardiovascular monitoring, and regulatory barriers — but does not list the participating companies, any specific regulatory changes, or follow-up actions. No motions, votes, or formal agency decisions are recorded in the provided excerpt.
Why it matters: statements about reducing regulatory barriers at HHS could affect how digital health products are reviewed, marketed and used by patients, and could have implications for privacy, clinical oversight and device safety. The transcript does not specify which regulations would change, which HHS offices were involved, or any timeline for policy work.
